Payment overview · 2025
General Payments
$144.30
7 reported records · 3 companies
Healthcare provider profile · identity verified
William Lewis Mckay, DO
Allopathic & Osteopathic Physicians|Family Medicine · MOUNT VERNON, MO · NPI 1265417331
Verified facts
What the public records show
CMS Open Payments records show William Lewis Mckay, DO received $144.30 in general payments during 2025 across 7 reported records.
ABBVIE INC. accounted for 56.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $81.32 | 56.4% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.59 | 24.0% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $28.39 | 19.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $144.30 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $81.32 | 4 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $28.39 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.83 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 262 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 258 | 31 |
| Atorvastatin Calcium | Atorvastatin Calcium | 250 | 48 |
| Lisinopril | Lisinopril | 225 | 43 |
| Omeprazole | Omeprazole | 212 | 35 |
| Gabapentin | Gabapentin | 192 | 34 |
| Amlodipine Besylate | Amlodipine Besylate | 173 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 166 | 31 |
| Trazodone Hcl | Trazodone Hcl | 154 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 150 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 136 | 22 |
| Sertraline Hcl | Sertraline Hcl | 123 | 14 |
| Finasteride | Finasteride | 103 | 17 |
| Meloxicam | Meloxicam | 102 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 92 | 21 |
| Celecoxib | Celecoxib | 88 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 83 | 13 |
| Montelukast Sodium | Montelukast Sodium | 82 | 19 |
| Simvastatin | Simvastatin | 76 | 16 |
| Carvedilol | Carvedilol | 72 | 16 |
| Metformin Hcl | Metformin Hcl | 72 | 17 |
| Levetiracetam | Levetiracetam | 71 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 71 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 70 | suppressed |
| Furosemide | Furosemide | 66 | 11 |
| Losartan Potassium | Losartan Potassium | 66 | 13 |
| Risperidone | Risperidone | 66 | suppressed |
| Potassium Chloride | Potassium Chloride | 63 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 60 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 59 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 57 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 56 | suppressed |
| Mirtazapine | Mirtazapine | 53 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 52 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 50 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 49 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 47 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 45 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 45 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 44 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 44 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 43 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 42 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Baclofen | Baclofen | 39 | suppressed |
| Fentanyl | Fentanyl | 38 | suppressed |
| Ibuprofen | Ibuprofen | 38 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 38 | suppressed |
| Alprazolam | Alprazolam | 37 | 12 |
| Famotidine | Famotidine | 37 | suppressed |
| Pregabalin | Pregabalin | 37 | suppressed |
| Lorazepam | Lorazepam | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 29 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 28 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Xtampza Er | Oxycodone Myristate | 26 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 25 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Verapamil Er | Verapamil Hcl | 24 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Allopurinol | Allopurinol | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 13 | suppressed |
| Eliquis | Apixaban | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 12 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 11 | suppressed |
| Olanzapine Odt | Olanzapine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $144.30 · 7 records | ABBVIE INC. | Cologuard Collection Kit, Senza, The Cologuard Plus Collection Kit, VRAYLAR | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error